

**Pharmaquinone® 99% Active Ingredient**  
**Vitamin K2 as MK-7**

# PDS

Product Data Sheet

14.01.2026

Document is subject to updates

## Content

|            |   |    |
|------------|---|----|
| Section 1  | Product Identity and Form.....  | 3  |
| Section 2  | Responsible for Product Development. Research and Regulatory Affairs.....   | 3  |
| Section 3  | Manufacturing and Quality Assurance/Quality Control Information.....        | 3  |
| Section 4  | Lot Number System. Product Storage.Packaging and Labelling Information..... | 4  |
| Section 5  | Certifications and Compliance.....  | 4  |
| Section 6  | Regulatory Status and IPR.....  | 5  |
| Section 7  | Food Safety System.....   | 7  |
| Section 8  | Origin and Composition.....   | 7  |
| Section 9  | Nutritional Profile.....  | 8  |
| Section 10 | Allergens on Production Line.....   | 8  |
| Section 11 | Product Specification.....  | 9  |
| Section 12 | Certificate of Analysis.....  | 11 |
| Section 13 | Flow chart.....   | 12 |

## Section 1 Product Identity and Form

|                             |  |
|-----------------------------|--|
| Product name                | Pharmaquinone® 99% Active Ingredient,<br>Vitamin K2 as MK-7                    |
| SKU code                    | K2MK7  |
| CAS number                  | 2124-57-4  |
| Chemical names              | Menaquinone-7 (MK-7)   |
| Common name                 | Vitamin K2   |
| General product information | Synthetic Vitamin K2 as all-trans MK-7 for use in food and dietary supplements |
| Country of origin           | Poland   |

## Section 2 Responsible for Product Development, Research and Regulatory Affairs

|  |  |
|--|--|
| Product developer marketing responsible,<br>IPR holder and regulatory affairs<br>Office and postal address | Vitasynth sp. z o. o.<br><br>4G Macieja Rataja Street<br>05-850 Koprki<br>Poland |
| Telephone  | +48 734 475 296  |
| Info   | sales@pharmaquinone.com  |
| Web  | www.pharmaquinone.com  |

## Section 3 Manufacturing and Quality Assurance/Quality Control Information

|  |   |
|--|---|
| QA/QC and control                        | Vitasynth Sp. z o.o.  |
| Manufacturer                             | Vitasynth Sp. z o.o.  |
| Manufacturing process                    | Multi-stage organic synthesis of vitamin MK7 from menadione, geraniol and farnesol                  |
| Manufacturing flow chart                 | See section 13  |
| Quality Assurance Systems                | See section 5 for details   |
| Certificates available upon request      |   |
| Residual solvent in accordance           | See section 6 for details   |
| Irradiation or chemical sterilization    | No irradiation or chemical sterilization is used during production. See section 6 Regulatory Status |
| Traceability system for product identity | In place  |
| Last revision of QA/QC systems           | 2025  |

## Section 4 Lot Number System. Product Storage. Packaging and Labelling Information

|   |   |
|---|---|
| Packaging and labelling   | HDPE bottles (high density polyethylene) intended for contact with food, protecting light-sensitive contents.   |
| Storage conditions  | The packaged product should be stored at 5-25°C/ 41-77°F. Protect from light and excessive heat. The product is light sensitive, and exposure may deteriorate K2 activity considerably. Avoid excessive humidity.   |
| Batch/lot numbering system  | APIyymm-n<br>API – the Active Powder Ingredient<br>yymm - the date format (year, month)<br>n -production number of the month  |
| Label information   | Product name and SKU code.<br>Batch no., manufacturing date & retest date.<br>Handling precautions.<br>Vitasynth contact information.   |
| Recommended restriction /<br>limitation on finished product label | Market specific labelling is implemented where required<br><br>Vitamin K2 may counteract the effects of anticoagulation therapy, and therefore is not recommended for patients on blood-thinning medications. The maximal daily dose in food supplement of 0.2 mg should not be exceeded. |

## Section 5 Certifications and Compliance

| Certification   | Status    | Third Party               |
|-----------------|-----------|---------------------------|
| Kosher          | Certified | EarthKosher               |
| Halal           | Certified | Polish Institute of Halal |
| Vegan           | Certified | Vegan Society             |
| FDA             | Statement | NA                        |
| cGMP            | Statement | NA                        |
| HACCP           | Certified | TÜV Rheinland             |
| ISO (FSSC22000) | Certified | TÜV Rheinland             |
| Non-GMO         | Statement | NA                        |

## Section 6 Regulatory Status and IPR

### Compliance with Regulations

Pharmaquinone® products are identical to already authorized under Regulation (EC) 258/97 novel foods and these authorizations are not data protected according to the requirements of Article 26 of Regulation (EU) 2015/2283. Therefore Pharmaquinone® products have been placed in the EU market without a dedicated application. The specifications and conditions of use of Pharmaquinone® products are in line with the authorized specifications and conditions of use as set out in the Union list of authorized novel foods and/or the implementing Regulations authorizing these substances in accordance with Implementing Regulation (EU) 2018/1023 of 23 July 2018 correcting Implementing Regulation (EU) 2017/2470 establishing the Union list of novel foods.

### Compliance to Regulations in Europe and the US

|                     |  |
|---------------------|--|
| GMO                 | Complies with Regulation (EC) 1829/2003, including amended Directive 2001/18/EC  |
| Ionizing radiation  | Complies with Directive 1999/2/EC product has not been sterilized  |
| Contaminants/toxins | Complies with Regulation (EU) 2023/915 of 25 April 2023 on maximum levels for certain contaminants in food                       |
| Pesticides          | Complies with Regulations (EC) 396/2005  |
| Residual Solvents   | Complies with good manufacturing practice, Directive 2009/32/EC and Ph. Eur. <2.4.24>/ USP <467> Residual Solvents requirements. |
| Palm, Soy           | Free of palm and soy   |
| Lactose, Gluten     | Free of lactose or gluten  |
| BSE/TSE             | Complies with good manufacturing practice and Regulation (EC) 999/2001.  |
| Prop 65             | Does not contain compounds listed in California Proposition 65   |
| Nano material       | No nanomaterial substances as per definition of Regulation (EU) 1169/2011  |
| WADA                | Do not contain any substances included in the prohibited list of the World Anti-Doping Agency (WADA)                             |

**Stability Protocol**

Stability program follows ICH Guideline to meet market specific requirements.

|  |  |  |   |   |                              |                    |                                |                     |                                      |                     |
|--|--|--|---|---|------------------------------|--------------------|--------------------------------|---------------------|--------------------------------------|---------------------|
| <b>Product name:</b> Pharmaquinone 99% Active Ingredient<br>Vitamin K2 as MK-7 |  |  | <b>Batch number:</b><br>RD-S01-MK7-2020.05.08 |   | <b>Mfg. date:</b><br>05.2020 |                    | <b>Retest date:</b><br>05.2023 |                     | <b>Packaging:</b><br>HDPE containers |                     |
| <b>Study: Long term</b><br>Time period: 36 months                              |  | <b>Storage condition:</b> 25 ± 2°C<br>60 ± 5% RH |   | <b>Time period covered by data at submission: 36 months</b> |                              |                    |                                |                     |                                      |                     |
| <b>TESTS</b>   | <b>REQUIREMENTS</b>                          | <b>METHOD</b>                                    | <b>Result (0M)</b>                            | <b>Result (3M)</b>  | <b>Result (6M)</b>           | <b>Result (9M)</b> | <b>Result (12M)</b>            | <b>Result (18M)</b> | <b>Result (24M)</b>                  | <b>Result (36M)</b> |
| <b>Description</b>   | Yellow crystalline powder                    | Visual assessment                                | Comply  | Comply  | Comply                       | Comply             | Comply                         | Comply              | Comply                               | Comply              |
| <b>Assay of vitamin K2 (MK7)</b>   | Not less than 99.0 % - not more than 101.0 % | UPLC method                                      | 100.75 %                                      | 100.48 %  | 100.65 %                     | 100.33 %           | 100.61 %                       | 100.25 %            | 99.96 %                              | 99.84 %             |
| <b>Assay of vitamin K2 (MK7)</b>   | Not less than 99.0 % - not more than 101.0 % | USP method                                       | 100.49 %                                      | 100.72 %  | 100.72 %                     | 100.46 %           | 100.34 %                       | 100.37 %            | 99.65 %                              | 99.50 %             |
| <b>Related substances</b><br>Total impurities                                  | Not more than 1.00 %                         | UPLC method                                      | 0.21 %  | 0.17 %  | 0.19 %                       | 0.22 %             | 0.21 %                         | 0.22 %              | 0.28 %                               | 0.27 %              |
| <b>Isomeric purity</b><br>Content of cis-menaquinone-7                         | Not more than 1.00 %                         | USP method                                       | Not detected                                  | Not detected  | Not detected                 | Not detected       | Not detected                   | Not detected        | Not detected                         | Not detected        |
| <b>Loss on drying</b>  | Not more than 0.50 %                         | Ph. Eur.<2.2.32>                                 | 0.09 %  | 0.11 %  | 0.00 %                       | 0.00 %             | 0.05 %                         | 0.12 %              | 0.29 %                               | 0.11 %              |

*This document is the property of Vitasynt. External use and copying without explicit permission from Vitasynt is prohibited.*

VITASYNTH sp. z o. o. 4G Macieja Rataja St., Koprki (05-850), Poland

### Intellectual Property Rights/Patents Granted/Patent Pending

To the best of our knowledge, the Product Pharmaquinone<sup>®</sup>. Vitamin K2 as MK-7 does not infringe any patent rights, rights in inventions, copyright and related rights in information (including protected know-how, confidentiality and trade secrets) (“IPRs”), belonging to a third party based on the comprehensive overview of the patents’ situation (granted and pending) in Europe.

### Tariff Code, FDA Registration and Compendial Standard

|                                     |  |
|-------------------------------------|--|
| EU export tariff code               | 2936 29 00 00  |
| US import tariff code               | 2936 29 50 50  |
| U.S. FDA Registration Vitasynth No. | 18752137180  |
| DUNS Vitasynth No.                  | 25446420   |
| Compendial standard                 | USP monograph for menaquinone-7 and in-house methods |

### Section 7 Food Safety System

Pharmaquinone<sup>®</sup> product. Vitamin K2 as MK-7 is a generic of the well-established and safe for human consumption original active ingredient, which has achieved GRAS in USA and novel food status in EU. The product is intended for use in the manufacturing of food products, including food supplements. Our process ensures the best quality and accordance to European novel food specification, being accepted by the Health Authorities as a reference for the manufacturers.

### Section 8 Origin and Composition

| Name ingredient | Origin             | CAS       | Concentration | Manufacturer | GMO status |
|-----------------|--------------------|-----------|---------------|--------------|------------|
| Menaquinone-7   | Chemical synthesis | 2124-57-4 | NLT 99%       | Vitasynth    | non-GMO    |

## Section 9 Nutritional Profile

| Component                           | Typical value per 100 g |
|-------------------------------------|-------------------------|
| Total calories                      | NA                      |
| Total fat                           | NA                      |
| whereof saturated fatty acids       | NA                      |
| whereof monounsaturated fatty acids | NA                      |
| whereof polyunsaturated fatty acids | NA                      |
| Carbohydrates                       | NA                      |
| Sugar                               | NA                      |
| Fiber                               | NA                      |
| Protein                             | NA                      |
| Salt                                | NA                      |
| Vitamin K2 as MK7                   | NLD 99%                 |

## Section 10 Allergens on Production Line

Free from allergens in compliance with EU Directive 1169/2011 Annex II

| Raw material/allergen                                       | Presence in Pharmaquinone® Product | Presence on production line for other products |
|---|------------------------------------|--|
| Cereals containing gluten <sup>1</sup> and products thereof | No                                 | No   |
| Crustaceans and products thereof                            | No                                 | No   |
| Eggs and products thereof                                   | No                                 | No   |
| Fish and products thereof                                   | No                                 | No   |
| Peanuts and products thereof                                | No                                 | No   |
| Soybeans and products thereof                               | No                                 | No   |
| Milk and products thereof (including lactose)               | No                                 | No   |
| Nuts <sup>2</sup> and products thereof                      | No                                 | No   |
| Celery and products thereof                                 | No                                 | No   |
| Mustard and products thereof                                | No                                 | No   |
| Sesame seeds and products thereof                           | No                                 | No   |
| Sulphur dioxide and sulphites <sup>3</sup>                  | No                                 | No   |
| Lupin and products thereof                                  | No                                 | No   |
| Molluscs and products thereof                               | No                                 | No   |

<sup>1</sup> namely: wheat, rye, barley, oats, spelt, kamut or their hybridized strains.

<sup>2</sup> namely: almonds (*Amygdalus communis* L.), hazelnuts (*Corylus avellana*), walnuts (*Juglans regia*), cashews (*Anacardium occidentale*), pecan nuts (*Carya illinoensis* (Wangenh.) K. Koch), Brazil nuts (*Bertholletia excelsa*), pistachio nuts (*Pistacia vera*), macadamia or Queensland nuts (*Macadamia ternifolia*)

<sup>3</sup> at concentrations of more than 10 mg/kg or 10 mg/litre in terms of the total SO<sub>2</sub> which are to be calculated for products as proposed ready for consumption or as reconstituted according to the instructions of the manufacturers

***This document is the property of Vitasynth. External use and copying without explicit permission from Vitasynth is prohibited.***

VITASYNTH sp. z o. o. 4G Macieja Rataja St., Koprki (05-850), Poland

## Section 11 Product Specification

|                    |  |
|--------------------|--|
| Product name       | Pharmaquinone®99% Active Ingredient. Vitamin K2 as MK-7                          |
| SKU codes          | K2MK7  |
| Vitamin K2 content | NLT 99.0% K2 as all-trans MK-7   |
| Packaging          | HDPE bottles intended for contact with food, protecting light-sensitive contents |
| Specification code | SPK/KJ/001 Rev. 09   |

| TESTS   | REQUIREMENTS                             | METHOD                               |
|---|--|--------------------------------------|
| <b>Description</b>  | Yellow crystalline powder                | Visual assessment                    |
| <b>Identification</b>   |  |                                      |
| IR  | Corresponds to the standard IR spectrum  | IR method*** ANL/KJ/007              |
| HPLC  | Corresponds to the standard HPLC profile | UPLC method*/USP method** ANL/KJ/007 |
| <b>Vitamin K2 (as all-trans MK7) assay</b><br>(calculated on the as-is basis) | 99.0 % - 101.0 %                         | UPLC method*/USP method** ANL/KJ/007 |
| <b>Limit of Menaquinone-6</b>   | Absent                                   | UPLC method*/USP method** ANL/KJ/007 |
| <b>Related substances</b>   |  |                                      |
| Single unknown impurity   | ≤ 0.5 %                                  | UPLC method* ANL/KJ/007              |
| Total impurities  | ≤ 1.0 %                                  |                                      |
| <b>Isomeric purity</b>  |  |                                      |
| <b>Content of cis-menaquinone-7</b>   | ≤ 1.0 %                                  | USP method** ANL/KJ/007              |
| <b>Loss on drying</b>   | ≤ 0.5 %                                  | TGA method*** ANL/KJ/007             |
| <b>Sulphated ash</b>  | ≤ 0.1 %                                  | Ph. Eur. <2.4.14>                    |
| <b>Residual solvents</b>  |  |                                      |
| Acetone   | ≤ 1500 ppm                               | GC method**** ANL/KJ/007             |
| Ethyl acetate   | ≤ 500 ppm                                |                                      |
| <b>Metal content</b>  |  |                                      |
| Arsenic   | ≤ 0.5 ppm                                |                                      |
| Cadmium   | ≤ 1 ppm                                  | ICP-MS method*** ANL/KJ/007          |
| Lead  | ≤ 3 ppm                                  |                                      |
| Mercury   | ≤ 0.1 ppm                                |                                      |

\* in-house UPLC method based on *J. Pharm. Biomed. Anal.* 135, 116-125



\*\* in accordance with Dietary Supplement Monograph, Menaquinone-7, USP-NF

\*\*\* in-house method

\*\*\*\* in-house method, validated according to ICH Guideline Q3C(R9) and Q2(R2)



Typical profile of residual solvents



## Shelf life, storage and handling

36 months from manufacture. The product should be stored at temperature 5-25°C / 41-77°F, in a dry place. Protect from light.

## Section 12 Certificate of Analysis



### Certificate of analysis

|                                   |   |
|-----------------------------------|---|
| <b>Product name</b>               | Pharmaquinone® 99% Active Ingredient, Vitamin K2 as MK-7  |
| <b>SKU code</b>                   | K2MK7   |
| <b>Batch number</b>               |   |
| <b>Retest date</b>                | 36 months from manufacture  |
| <b>Manufacturing date</b>         |   |
| <b>Expiry date</b>                |   |
| <b>Storage</b>                    | The product should be stored at temperature 5-25°C / 41-77°F, in a dry place. Protect from light. |
| <b>Product specification code</b> | SPK/KJ/001 rev.09   |

| TESTS  | REQUIREMENTS                             | METHOD  | RESULTS |
|--|--|---|---------|
| <b>Description</b>   | Yellow crystalline powder                | Visual assessment   |         |
| <b>Identification</b>  |  |   |         |
| IR   | Corresponds to the standard IR spectrum  | IR method <sup>**</sup> ANL/KJ/007                              |         |
| HPLC   | Corresponds to the standard HPLC profile | UPLC method <sup>*</sup> / USP method <sup>***</sup> ANL/KJ/007 |         |
| <b>Vitamin K2 (as all-trans MK-7) assay</b><br>(calculated on the as-is basis) | 99.0 % - 101.0 %                         | UPLC method <sup>*</sup> / USP method <sup>***</sup> ANL/KJ/007 |         |
| <b>Limit of Menaquinone-6</b>  | Absent                                   | UPLC method <sup>*</sup> / USP method <sup>***</sup> ANL/KJ/007 |         |
| <b>Related substances</b>  |  |   |         |
| Single unknown impurity  | ≤ 0.5 %                                  | UPLC method <sup>*</sup> ANL/KJ/007                             |         |
| Total impurities   | ≤ 1.0 %                                  |   |         |
| <b>Isomeric purity</b>   |  |   |         |
| Content of cis-menaquinone-7   | ≤ 1.0 %                                  | USP method <sup>***</sup> ANL/KJ/007                            |         |
| <b>Loss on drying</b>  | ≤ 0.5 %                                  | TGA method <sup>****</sup> ANL/KJ/007                           |         |
| <b>Sulphated ash</b>   | ≤ 0.1 %                                  | Ph. Eur. <2.4.14>   |         |
| <b>Residual solvents</b>   |  |   |         |
| Acetone  | ≤ 1500 ppm                               | GC method <sup>****</sup> ANL/KJ/007                            |         |
| Ethyl acetate  | ≤ 500 ppm                                |   |         |
| <b>Heavy metals</b>  |  |   |         |
| Arsenic  | ≤ 0.5 ppm                                |   |         |
| Cadmium  | ≤ 1 ppm                                  | ICP-MS method <sup>****</sup> ANL/KJ/007                        |         |
| Lead   | ≤ 3 ppm                                  |   |         |
| Mercury  | ≤ 0.1 ppm                                |   |         |

<sup>\*</sup> in-house method based on J. Pharm. Biomed. Anal. 135, 116-125  
<sup>\*\*</sup> in accordance with Dietary Supplement Monograph, Menaquinone-7, USP-NF  
<sup>\*\*\*</sup> in-house method  
<sup>\*\*\*\*</sup> in-house method, validated according to ICH Guideline Q3C(R9) and Q2(R2)



## Section 13 Flow chart

